Literature DB >> 32538147

Multiple ways to kill bacteria via inhibiting novel cell wall or membrane targets.

George A Naclerio1,2, Herman O Sintim1,2,3.   

Abstract

The rise of antibiotic-resistant infections has been well documented and the need for novel antibiotics cannot be overemphasized. US FDA approved antibiotics target only a small fraction of bacterial cell wall or membrane components, well-validated antimicrobial targets. In this review, we highlight small molecules that inhibit relatively unexplored cell wall and membrane targets. Some of these targets include teichoic acids-related proteins (DltA, LtaS, TarG and TarO), lipid II, Mur family enzymes, components of LPS assembly (MsbA, LptA, LptB and LptD), penicillin-binding protein 2a in methicillin-resistant Staphylococcus aureus, outer membrane protein transport (such as LepB and BamA) and lipoprotein transport components (LspA, LolC, LolD and LolE). Inhibitors of SecA, cell division protein, FtsZ and compounds that kill persister cells via membrane targeting are also covered.

Entities:  

Keywords:  antimicrobial resistance; cell membrane; cell wall; multidrug-resistant bacteria; new bacterial targets; small-molecule antimicrobials

Mesh:

Substances:

Year:  2020        PMID: 32538147     DOI: 10.4155/fmc-2020-0046

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  13 in total

1.  The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by Pseudomonas aeruginosa.

Authors:  Gang Wang; Jean-Michel Brunel; Jean-Michel Bolla; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.

Authors:  Ronit Vogt Sionov; Doron Steinberg
Journal:  Microorganisms       Date:  2022-06-16

3.  Comparative Studies to Uncover Mechanisms of Action of N-(1,3,4-Oxadiazol-2-yl)benzamide Containing Antibacterial Agents.

Authors:  George A Naclerio; Kenneth I Onyedibe; Caroline W Karanja; Uma K Aryal; Herman O Sintim
Journal:  ACS Infect Dis       Date:  2022-03-17       Impact factor: 5.578

4.  Mechanistic Studies and In Vivo Efficacy of an Oxadiazole-Containing Antibiotic.

Authors:  George A Naclerio; Nader S Abutaleb; Kenneth I Onyedibe; Caroline Karanja; Hassan E Eldesouky; Hsin-Wen Liang; Alexandra Dieterly; Uma K Aryal; Tiffany Lyle; Mohamed N Seleem; Herman O Sintim
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

5.  N-(1,3,4-Oxadiazol-2-yl)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae.

Authors:  George A Naclerio; Nader S Abutaleb; Marwa Alhashimi; Mohamed N Seleem; Herman O Sintim
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

6.  Computational Design and Development of Benzodioxane-Benzamides as Potent Inhibitors of FtsZ by Exploring the Hydrophobic Subpocket.

Authors:  Valentina Straniero; Victor Sebastián-Pérez; Lorenzo Suigo; William Margolin; Andrea Casiraghi; Martina Hrast; Carlo Zanotto; Irena Zdovc; Antonia Radaelli; Ermanno Valoti
Journal:  Antibiotics (Basel)       Date:  2021-04-15

7.  Structural systems pharmacology: A framework for integrating metabolic network and structure-based virtual screening for drug discovery against bacteria.

Authors:  Elmira Nazarshodeh; Sayed-Amir Marashi; Sajjad Gharaghani
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

8.  ElyC and Cyclic Enterobacterial Common Antigen Regulate Synthesis of Phosphoglyceride-Linked Enterobacterial Common Antigen.

Authors:  Joseph F Carr; David E Bautista; Ashutosh K Rai; Wei Wang; Angela M Mitchell
Journal:  mBio       Date:  2021-11-23       Impact factor: 7.867

9.  Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo.

Authors:  George A Naclerio; Nader S Abutaleb; Daoyi Li; Mohamed N Seleem; Herman O Sintim
Journal:  J Med Chem       Date:  2020-10-06       Impact factor: 8.039

Review 10.  Emerging peptide antibiotics with therapeutic potential.

Authors:  Gregory Upert; Anatol Luther; Daniel Obrecht; Philipp Ermert
Journal:  Med Drug Discov       Date:  2020-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.